Biotechnological company Selvita will conduct a public offer of their shares to raise capital for the development of innovative oncology projects. In the next four years, it will allocate PLN 290 million, of which PLN 140 million is to be obtained from investors.
Selvita wants to allocate their funds to the development of SEL120, which is to fight acute myelogenous leukemia and for four innovative platforms: targeted therapies, cancer cell metabolism with immuno-metabolism, immunological and immuno-oncological as well as a biological molecules tooling platform.
Selvita successfully commercializes innovative projects. Its leukemia drug SEL24 is the first Polish drug approved for clinical trials in the US.
More about the SEL120 drug development project:
